$ 712.80
Details
The Human NOV ELISA quantitates Hu NOV in human serum, plasma, or cell culture medium. The assay will exclusively recognize both natural and recombinant Hu NOV. Principle of the method The Human NOV solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) is designed to measure the amount of the target bound between a matched antibody pair. A target-specific antibody has been pre-coated in the wells of the supplied microplate. Samples, standards, or controls are then added into these wells and bind to the immobilized (capture) antibody. The sandwich is formed by the addition of the second (detector) antibody, a substrate solution is added that reacts with the enzyme-antibody-target complex to produce measurable signal. The intensity of this signal is directly proportional to the concentration of target present in the original specimen. Rigorous validation Each manufactured lot of this ELISA kit is quality tested for criteria such as sensitivity, specificity, precision, and lot-to-lot consistency. See manual for more information on validation.The CCN (CTGF/Cyr61/NOV) family of genes presently consists of six distinct members, which encode proteins that participate in fundamental biological processes such as cell proliferation, adhesion, migration, differentiation, wound healing, angiogenesis and several pathologies including fibrosis and tumorigenesis. Whereas Cyr61 and CTGF act as positive regulators of cell growth, nov (nephroblastoma overexpressed, CCN3 or NOVH) provides the first example of a CCN protein with negative regulatory properties and the first example of aberrant expression being associated with tumor development. In animals and humans increased expression of nov is detected in tissues where calcium is a key regulator, such as the adrenal gland, central nervous system, bone and cartilage, heart muscle and kidney. The nov protein associates with Notch1 extracellular domain and inhibits myoblast differentiation via Notch signaling pathway.
